Hardman & Co: Equity issue ensures growth is not adjourned

Burford has placed 10.41m new shares with institutional investors through an accelerated bookbuild. The price per share was 1850p, making a total of £192.6m ($251.2m) raised before expenses. The funding will be applied to business expansion, with new geographies such as parts of the United States that have not been fully addressed yet, Australia and Germany specifically mentioned as well as adding to the team in existing locations. The announcement also mentions new products, which have been the topic of recent press releases, and it is clear that Burford has every intention of pushing its growth further.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/burford-capital-documents/05.10.18-equity-issue-ensures-growth-is-not-adjourned.pdf

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.